3CH Share Price

Open 4.50 Change Price %
High 4.50 1 Day 0.00 0.00
Low 4.50 1 Week 0.00 0.00
Close 4.50 1 Month 0.00 0.00
Volume 87 1 Year 0.00 0.00
52 Week High 19.97
52 Week Low 7.23
3CH Important Levels
Resistance 2 4.50
Resistance 1 4.50
Pivot 4.50
Support 1 4.50
Support 2 4.50
ETR Germany Most Active Stocks
CBK 7.68 5.35%
CBK 7.68 5.35%
DBK 17.87 2.82%
DBK 17.87 2.82%
DTE 15.59 2.16%
DTE 15.59 2.16%
DTE 15.59 2.16%
DTE 15.59 2.16%
DTE 15.59 2.16%
EOAN 6.35 -2.01%
More..
ETR Germany Top Gainers Stocks
EMQ 0.03 50.00%
S9H 0.16 45.45%
GFK 43.83 30.68%
GFK 43.83 30.68%
SMK 0.06 20.00%
5M71 39.00 13.70%
VOW5 26.05 10.85%
WEG1 5.30 10.19%
ARRC 8.19 9.20%
BPG 0.36 9.09%
More..
ETR Germany Top Losers Stocks
MPI 0.25 -98.98%
MPI 0.25 -98.98%
APL 2.60 -34.18%
APL 2.60 -34.18%
APL 2.60 -34.18%
CEW3 0.21 -19.23%
ITN 0.41 -10.87%
M6YA 0.75 -10.71%
YOC 3.40 -10.53%
SNG 3.78 -7.80%
More..

Chelsea Therapeutics (ETR: 3CH)

3CH Technical Analysis 5
As on 8th May 2014 3CH Share Price closed @ 4.50 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 4.50 & Strong Sell for SHORT-TERM with Stoploss of 4.50 we also expect STOCK to react on Following IMPORTANT LEVELS.
3CH Target for December
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
3CH Other Details
Segment EQ
Market Capital 0.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.chelseatherapeutics.com
3CH Address
3CH
3530 Toringdon Way
Suite 200
Charlotte, NC 28277
United States
Phone: 704-341-1516
3CH Latest News
Interactive Technical Analysis Chart Chelsea Therapeutics ( 3CH ETR Germany )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Chelsea Therapeutics
3CH Business Profile
Chelsea Therapeutics International, Ltd., a development stage pharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of various human diseases. It is developing Northera (droxidopa), a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (Neurogenic OH) in patients with primary autonomic failure, dopamine-ß-hydroxylase, and deficiency and non-diabetic autonomic neuropathy. The company is also evaluating droxidopa in other potentially norepinephrine-related conditions and diseases, including intradialytic hypotension, fibromyalgia, freezing of gait, and adult attention deficit hyperactivity disorders. In addition, it is has a portfolio of metabolically inert antifolates for the treatment of rheumatoid arthritis, as well as for the treatment of multiple other autoimmune disorders, including psoriasis, Crohn’s diseases, uveitis, ankylosing spondylitis, inflammatory bowel diseases, cancer, and other immunological disorders. The company was founded in 2002 and is headquartered in Charlotte, North Carolina.